Authors: Taylor, Matthew J.¹; Elgazzar, Heba A.²; Chaplin, Stephen¹; Goldsmith, David³; Molony, Donald A.⁴

Source: Current Medical Research and Opinion, Volume 24, Number 2, February 2008 , pp. 601-608(8)

Publisher: Informa Healthcare

Abstract:

Objective: The overall objective of this study was to estimate the costs and outcomes associated with treatment with sevelamer for hyperphosphataemia compared with calcium-based binders.

Methods: Using published data on mortality and hospitalisation rates, a Markov model was developed to predict health outcomes and associated costs for the treatment of hyperphosphataemia using either sevelamer or calcium binders in chronic kidney disease patients who had recently started haemodialysis. Patient outcomes were modelled for 5 years, and incremental cost-effective ratios (ICERs) were calculated for sevelamer relative to calcium carbonate and calcium acetate binders. The perspective adopted was that of the UK National Health Service.

Results: The total 5-year discounted treatment cost for patients treated with sevelamer is £24 216, while for the calcium carbonate group total cost was £17 695. This is an incremental cost of £6521 per sevelamer-treated patient over 5 years. Patients receiving sevelamer can be expected to experience 2.70 quality-adjusted life years (QALYs) compared to 2.46 for those treated with calcium carbonate (i.e. an incremental gain of 0.24 QALYs). This results in an incremental cost per QALY of £27 120 and an incremental cost per life year gained of £15 508. Results were similar with calcium acetate.

Conclusion: Together with the unique morbidity and mortality benefits, this study suggests that treatment with sevelamer confers clinical benefits with a modest investment of additional economic resources.

Keywords: CALCIUM CARBONATE; COST-EFFECTIVENESS; END STAGE RENAL DISEASE; SEVELAMER

Document Type: Research article

DOI: http://dx.doi.org/10.1185/030079908X260853

Affiliations: 1: York Health Economics Consortium Ltd, University of York, UK 2: Global Health Outcomes, Genzyme Therapeutics, Oxford, UK, and Boston, Massachusetts, USA 3: Guy's and St Thomas' Hospitals, London, UK 4: Professor of Internal Medicine, University of Texas Health Science Center at Houston Medical School, Houston, Texas, USA

Publication date: 2008-02-01

More about this publication?

• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• General Information
• Journal Information
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General)
• By this author: Taylor, Matthew J. ;  Elgazzar, Heba A. ;  Chaplin, Stephen ;  Goldsmith, David ;  Molony, Donald A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers